Annual Review of Pharmacology and Toxicology ( IF 12.5 ) Pub Date : 2017-01-06 00:00:00 , DOI: 10.1146/annurev-pharmtox-010716-105055 Anthony P. Cardile 1 , Travis K. Warren 1 , Karen A. Martins 1 , Ronald B. Reisler 1 , Sina Bavari 1
Despite the unprecedented Ebola virus outbreak response in West Africa, no Ebola medical countermeasures have been approved by the US Food and Drug Administration. However, multiple valuable lessons have been learned about the conduct of clinical research in a resource-poor, high risk–pathogen setting. Numerous therapeutics were explored or developed during the outbreak, including repurposed drugs, nucleoside and nucleotide analogues (BCX4430, brincidofovir, favipiravir, and GS-5734), nucleic acid–based drugs (TKM-Ebola and AVI-7537), and immunotherapeutics (convalescent plasma and ZMapp). We review Ebola therapeutics progress in the aftermath of the West Africa Ebola virus outbreak and attempt to offer a glimpse of a path forward.
中文翻译：
埃博拉病毒会治愈吗？
尽管西非地区爆发了史无前例的埃博拉病毒爆发反应，但美国食品药品监督管理局尚未批准埃博拉病毒的医疗对策。但是，在资源贫乏，高风险，病原体环境下，已经进行了许多有关临床研究的宝贵经验。暴发期间探索或开发了许多治疗方法，包括重新用途的药物，核苷和核苷酸类似物（BCX4430，brincidofovir，favipiravir和GS-5734），基于核酸的药物（TKM-Ebola和AVI-7537）和免疫疗法（恢复期）等离子和ZMapp）。我们回顾了西非埃博拉病毒爆发后的埃博拉病毒治疗进展，并试图瞥见前进的道路。
京公网安备 11010802027423号